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Recurrent Cerebral Venous Thrombosis Associated 
with Elevated Factor VIII
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Jong S. Kim, M.D.
Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center
Cerebral venous thrombosis (CVT) rarely recurs, and the factors associated with a recurrence remain unclear. 
Recently, however, elevated plasma coagulation factor VIII has been considered a factor related to recurrent venous 
thromboembolism. Here we report a patient who had recurrent CVT associated with significantly elevated levels of 
factor VIII despite the chronic use of an antiplatelet agent. Factor IX was also elevated in this patient. These findings 
suggest that elevated factor VIII is a factor underlying the recurrence of CVT, and that prolonged anticoagulation 
therapy may have to be considered in patients with elevated coagulation factor levels.
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INTRODUCTION
Cerebral venous thrombosis (CVT) is an uncommon 
condition with a variety of clinical presentations and 
outcomes,
1 and hence definitive therapeutic and 
prevention strategies for CVT have not been esta-
blished.
1,2 Although anticoagulation therapy is used 
commonly in patients with CVT, a decision to initiate, 
continue, or withhold anticoagulation therapy in these 
patients should be made on the basis of the anticipated 
risk of recurrent thrombosis and possible hemorrhagic 
complications. Although it is known that CVT can 
be caused by pregnancy, hypercoagulable condition, 
inflammatory states, or collagen vascular diseases
1,3, the 
factors related to recurrent CVT remain unclear. Recent 
studies have addressed the hypothesis that elevated 
plasma factor VIII is an independent risk factor for 
recurrent venous thromboembolism.
4-6 However, there 
have been few reported cases of recurrent CVT with 
elevated plasma factor VIII, and to our knowledge no 
Korean cases have been described. To address this issue, 
here we report a patient who had recurrent episodes of 
CVT with elevated factor VIII despite prolonged use of 
an antiplatelet agent.
CASE REPORT
A 46-year-old woman developed severe generalized 
headache and vomiting. Sudden right postauricular area 
pain developed 10 days before admission, which spread Kim MJ, et al. Cerebral Venous Thrombosis Associated with Elevated Factor VIII
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Figure 3. Conventional angiogram findings. (A) Occlusion of 
the right jugular vein (arrowhead) and transverse sinus (arrow). 
(B) After suction thrombectomy, the filling of the right internal 
jugular vein and transverse sinus had improved.
Figure 1. Brain computed tomography (CT) scan and 
conventional angiogram acquired at the time of the first 
attack. (A) CT scan showing a low-density area on the left 
frontal area (arrow). (B) Angiography revealed a filling defect in 
the superior sagittal sinus and irregular filling in the left 
transverse sinus (arrowheads).
Figure 2. CT findings at the time of the second attack. (A) 
Transverse sinus thrombosis with cord sign is visible on the 
right side (arrow). (B) CT showing venous infarction with 
hemorrhagic transformation in the right temporal area.
to the frontal area. The headache was severe, and dull 
or throbbing in nature. She also complained of blurred 
vision at the time of admission. This patient did not 
have hypertension or diabetes mellitus, and she was a 
nonsmoker. She denied a history of orogenital ulcer, 
ocular diseases, oral contraceptive use, or regular ingestion 
of alcohol or drugs. On neurologic examination, she was 
alert and oriented. She showed no focal neurologic 
findings except for bilateral papilledema.
Four years before this admission, she had developed 
generalized tonic-clonic seizures and, based on angio-
graphic findings, was diagnosed as having superior 
sagittal sinus thrombosis. Cerebral venous infarction was 
found in the left frontal area (Fig. 1). At that time, her 
serum level of factor VIII was 216% (normal range 
60-120%) and that of factor IX was 238% (normal range 
60-120%). Plasma levels of fibrinogen, C-reactive 
protein, total protein S, protein C, and homocysteine 
were normal. She was negative for lupus anticoagulant, 
and only weakly positive for anticardiolipin antibody of 
IgM type. She was treated at that time with anticoa-
gulation therapy for 5 months, and then maintained with 
continuous antiplatelet (ticlopidine) therapy. Her serum 
levels of coagulation factor were not measured during 
the subsequent follow-up period.
On admission, a brain computed tomography scan 
showed hemorrhagic infarction in the right temporal 
area. High-density signals in the right jugular vein and 
transverse sinus suggested acute venous thrombosis 
(Fig. 2). Venous infarction with hemorrhagic trans-
formation was diagnosed. The laboratory results revealed 
a threefold elevation of plasma factor VIII (339%). 
Factor IX was also mildly elevated (151%). Her white 
blood cell count and hemoglobin levels were normal. 
Other laboratory results, such as C-reactive protein, 
fibrinogen, protein C, total protein S, and homocysteine, 
were within normal limits. We was negative for lupus 
anticoagulant, and only weakly positive for beta-2- 
glycoprotein of I-IgM type, and her thyroid functions 
including free thyroxin and thyroid-stimulating hormone 
were within normal ranges. Her blood type was A.
Multiple venous sinus thromboses were found on 
conventional angiography, and suction thrombectomy 
was performed on the right internal jugular vein (Fig. 3). 
Low-molecular-weight heparin (LMWH) and mannitol 
were administered. Her headache gradually improved 
and the papilledema disappeared after several days. 
Subcutaneous LMWH was switched to warfarin at the Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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time of discharge, and the target International Nor-
malized Ratio range of 2-3 was maintained. At a 
1-month follow-up her course remained uneventful.
DISCUSSION
Our patient had recurrent CVT despite the continuous 
use of an antiplatelet agent. Recurrent CVT is 
uncommon,
1,2 with an approximate annual rate of 5%.
2 
It has been suggested that the concurrent presence of 
cancer, high titer of antiphospholipid antibodies, or 
chronic inflammation are factors related to the recurrence 
of CVT.
1,3,7 Our patient did not have these risk factors, 
but showed significantly elevated plasma levels of factor 
VIII and moderately elevated plasma levels of factor IX.
Recently it was proposed that a high plasma level of 
factor VIII could be a risk factor for recurrent venous 
thrombosis.
4 In the Leiden Thrombophilia Study, factor 
VIII levels above 150 IU/dl(%) were associated with a 
fivefold increased risk of venous thrombosis.
8 Among 
patients with a factor VIII level above the 90th 
percentile, the likelihood of recurrence at 2 years was 
37%, as compared with a 5% likelihood among patients 
with lower levels.
4 Although not yet well recognized, 
elevated plasma factor VIII levels may not only be a 
factor related to the recurrence of CVT, but may itself 
also be a risk factor for CVT. In a recent study, elevated 
plasma factor VIII was considered to be the most 
important prothrombotic risk factor for CVT.
7
One may argue that these elevated clotting factors 
may represent an acute-phase reaction rather than the 
cause of the thrombosis. Unfortunately, plasma factor 
VIII was not measured in the chronic stage of disease 
in our patient. However, previous literature has illustrated 
that the high levels of factor VIII in patients with 
thrombosis persist over time.
4,5,9 Moreover, as in our 
case, a significant relationship was not detected between 
plasma levels of factor VIII and those of C-reactive 
protein.
4,9 Finally, although plasma levels of factor VIII 
may increase in patients with inflammation, cancer, or 
pregnancy,
1 our patient did not have these factors. The 
high levels of factor VIII can therefore be considered the 
cause rather than the consequence of venous thrombosis.
The etiology underlying the high plasma factor VIII 
levels remains unclear. An elevated von Willebrand 
factor and a non-O blood group have been considered 
important determinants of plasma factor VIII levels.
10,11 
In another study, a gene locus on chromosome 18 was 
shown to influence both factor VIII levels and 
susceptibility for thrombosis.
12 Therefore, certain genetic 
factors appear to predispose a subject to have elevated 
plasma factor VIII and recurrent thrombosis.
Interestingly, plasma factor IX was also elevated in 
our patient. According to a recent report, a high plasma 
factor IX level may also be related to a two- to threefold 
increased risk of venous thrombosis.
13 Since factor VIII 
is the cofactor of factor IXa in the activation of factor 
X, the concurrent increase in plasma factors VIII and IX 
may further increase the risk of CVT. However, the 
mechanism underlying the concomitant increase in these 
two coagulation factors remains unknown.
The treatment of CVT remains controversial. We 
successfully performed suction thrombectomy through 
the internal jugular vein in our patient. This treatment 
has been tried in the few reported cases,
14 but its 
efficacy has never been examined in controlled studies. 
Trials with heparin and other anticoagulants have not 
proved beneficial;
1 nevertheless, anticoagulants have 
been considered a standard therapy for CVT. Because of 
the risk of bleeding, however, long-term anticoagulant 
therapy is generally reserved for patients with a high 
risk of recurrent CVT.
Considering the variable clinical course of CVT, we 
cannot draw any definitive conclusion from our single 
case. Nevertheless, our findings in this patient suggest 
that antiplatelet therapy is not sufficient to prevent 
recurrent CVT in patients with significantly elevated 
coagulation factors. Factor VIII, and perhaps factor IX, 
may have to be routinely screened in patients with CVT, 
and prolonged anticoagulation therapy may have to be 
considered in those with elevated levels of these factors.
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